Results 1 to 10 of about 1,830 (159)

Case Report: Carbonic anhydrase inhibitor brinzolamide dramatically improved the morphology and also function of a patient with RS1 mutation [PDF]

open access: yesFrontiers in Pharmacology
X-linked retinoschisis (XLRS) is an inherited retinal disease caused by mutations in the RS1 gene, which encodes retinoschisin, a protein essential for maintaining the retinal structure during development.
Yue Ren   +16 more
doaj   +2 more sources

Effect of topical brinzolamide on visual function and waveform in patients of infantile nystagmus syndrome: A randomized control trial [PDF]

open access: yesIndian Journal of Ophthalmology
Purpose: To evaluate the effect of topical carbonic anhydrase inhibitor (brinzolamide) versus placebo on visual function and waveforms in infantile nystagmus syndrome (INS). Design: Prospective, placebo-controlled, double-blind, cross-over study. Methods:
Bhupendra Yadav   +7 more
doaj   +2 more sources

Sustained intraocular pressure-lowering effect and biocompatibility of a single subconjunctival administration of hydrogel-encapsulated nano-brinzolamide [PDF]

open access: yesJournal of Materials Science: Materials in Medicine
Brinzolamide is a widely used treatment for glaucoma, but its effectiveness relies on at least twice-daily dosing, which can be challenging for patient adherence.
Jiahao Xu   +6 more
doaj   +2 more sources

Stressing the limits of capillary blood in anti-doping analysis: perspectives on alkylamine-like stimulants and carbonic anhydrase II inhibitors in result management [PDF]

open access: yesFrontiers in Sports and Active Living
The establishment of an anti-doping rule violation extends beyond the mere detection of a prohibited substance. Current interpretation criteria rely primarily on urinary concentration estimates, which may be misleading due to high interindividual ...
Isabelle Karine da Costa Nunes   +7 more
doaj   +2 more sources

Intraocular pressure is a promising target for myopia control [PDF]

open access: yesJournal of Translational Medicine
Background Myopia presents a noteworthy global health concern, urging exploration of innovative treatments. The role of intraocular pressure (IOP) in regulating the progression of myopia has been controversial.
Peiyuan Wang   +16 more
doaj   +2 more sources

Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment [PDF]

open access: yesMaterials Today Bio
Glaucoma ranked second among the causes of blindness globally, necessitates the development of novel and effective therapeutic strategy. Anti-glaucoma eye drops as a topical dosage form are still considered as a method of choice for glaucoma treatment ...
Haroon Iqbal   +6 more
doaj   +2 more sources

Effects of brinzolamide on rabbit ocular blood flow in vivo and ex vivo [PDF]

open access: yesInternational Journal of Ophthalmology, 2018
AIM: To investigate if significant improvement of optic disc blood flow (ODBF) occurs after instillation of brinzolamide onto rabbit eyes. METHODS: Testing of bilateral intraocular pressure (IOP) and left ODBF in 10 male rabbits took place every 3h over
Ya-Ru Dong   +3 more
doaj   +1 more source

Quantification of Carbonic Anhydrase Inhibitors and Metabolites in Urine and Hair of Patients and Their Relatives

open access: yesBiology, 2022
Carbonic anhydrase inhibitors (CAIs) are prescription drugs also used in doping to dilute urine samples and tamper with urinalyses. Dorzolamide, brinzolamide, and acetazolamide are prohibited by the World Anti-Doping Agency.
Alfredo Fabrizio Lo Faro   +15 more
doaj   +1 more source

Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis

open access: yesFrontiers in Pharmacology, 2019
Background: Brinzolamide as a carbonic anhydrase inhibitor could be combined with other intraocular pressure (IOP) lowering drugs for glaucoma and ocular hypertension (OHT), but the efficacy was controversial.
Yuanzhi Liu   +5 more
doaj   +1 more source

Adjunctive antihypertensive therapy of primary glaucoma with a fixed combination drug of 1% brinzolamide and 0.5% timolol: efficacy and safety

open access: yesРоссийский офтальмологический журнал, 2023
Purpose: a comparative study of the efficacy and safety of the combination drug Brinzopt Plus and the original drug Azarga used as adjunctive therapy in patients with primary open-angle glaucoma (POAG) previously treated with latanoprost.Material and ...
S. Yu. Petrov   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy